cemiplimab (Libtayo)
Jump to navigation
Jump to search
Indications
- advanced cutanous squamous cell carcinoma
- advanced cutanous basal cell carcinoma previously treated with hedgehog pathway inhibitor
Dosage
- 3 mg/kg every 2 weeks
Adverse effects
- discontinuation in 13%
- pneumonitis, hypothyroidism, arthralgia, vitiligo common with PD-1 inhibitors[2]
- fatigue, somnolence, musculoskeletal pain
- rash, pruritus, infected neoplasm
- upper respiratory tract infection
- urinary tract infection, acute kidney injury
- colitis, diarrhea
- adrenal insufficiency
- anemia
- drug adverse effects of checkpoint inhibitor(s)
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
- inhibits PD-1 pathway
More general terms
References
- ↑ Kuznar W with expert critique by Klil-Drori AJ Cemiplimab Gains Approval for Advanced Squamous Cell Carcinoma. Durable responses with first systemic agent for this group of patients. MedPage Today. ASCO Reading Room 10.27.2018. https://www.medpagetoday.com/reading-room/asco/skin-cancer/75935
Migden MR, Rischin D, Schmults CD et al PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 2018; 379:341-351 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29863979 https://www.nejm.org/doi/full/10.1056/NEJMoa1805131 - ↑ 2.0 2.1 Marin-Acevedo JA, Chirila RM, Dronca RS. Immune Checkpoint Inhibitor Toxicities. Mayo Clinic Proc. July 2019. 94(7):1321-1329 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31272574
- ↑ Bankhead C First Immunotherapy Approved for Basal Cell Carcinoma - Objective responses in 27% of previously treated patients who received cemiplimab. MedPage Today February 10, 2021 https://www.medpagetoday.com/hematologyoncology/skincancer/91145